The Prince Charles Hospital
Chermside, Queensland, 4032, Australia
NCT Number: NCT07562217
The LIAISE study is a prospective observational study comparing the performance of load-incorporating echocardiographic parameters and conventional parameters in predicting adverse events among adult patients presenting to the ICU with sepsis. It will be conducted in hospitals in Australia, Hong Kong, South Africa, and Canada, with 199 patients recruited over 2 years. All included patients will receive an regular echocardiographic assessment and their haemodynamic parameters will be simultaneously recorded. Participants will be followed for up to 1 year after enrolment. Load incorporating parameters will be derived from regularly obtained echocardiography and haemodynamic data during offline analysis. The predictive value of cardiac parameters will be evaluated based on their statistical association with clinical outcomes.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Chermside, Queensland, 4032, Australia
Background Sepsis is a global killer, whereby an infection spreads throughout the body via the bloodstream. It often leads to lethal heart damage, "septic cardiomyopathy", with mortality rates for those affected soaring above 40%. To facilitate early and appropriate intervention for damaged hearts and improve their outcomes, accurate assessment of heart function, and proper prediction of their adverse events are crucial. However, conventional cardiac assessments cannot capture heart dysfunction accurately since they have a significant limitation called "load-dependency", which means these parameters' values are affected by loading conditions on the heart, such as blood pressure and circulating blood volume. In sepsis, as these loads on the heart dramatically change minute by minute, the values of cardiac assessment also fluctuate and frequently underestimates heart damage, failing to properly predict their adverse events. To address this, novel load-incorporating echocardiographic parameters can capture heart function more accurately regardless of these hemodynamic conditions, and previous data has demonstrated its better predictive value in cardiogenic shock cases where loading conditions similarly fluctuate. As a next step, this study seeks to elucidate their utility in patients with sepsis.
Aims
Hypothesis Load-incorporating echocardiographic parameters will be more accurate in predicting the incidence of adverse events within 30 days after ICU admission than conventional echocardiographic parameters.
Outcomes Primary outcome The incidence of all-cause death for 30 days after ICU admission
Secondary outcomes
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Day 30 after ICU admission
Time frame: 1 year after ICU admission
Incidence of and time to all-cause death or adverse cardiac event readmissions for 1 year after ICU admission
Time frame: during the initial index admission, between Day 0 and Day 30
Incidence and duration (days) of mechanical circulatory support, mechanical ventilation, renal replacement therapy, and vasoactive agent therapy during initial admission
Time frame: Day 3 to Day 5
Left ventricular ejection fraction increases ≥ 5% in echo from 3-5 days after ICU admission
Time frame: at Day 3 of ICU admission
Sequential Organ Failure Assessment score at Day 3 of index ICU admission will be assessed on a scale from 0 to 24, with higher scores indicating more severe organ failure.
Time frame: during the initial index admission, between Day 0 and Day 30
Time frame: during the initial index admission, between Day 0 and Day 30
Time frame: at 24 hour and 48 hour of index ICU admission
Time frame: Day 1 of index ICU admission
CSL
Contact information is provided by the study sponsor or research team.
The University of Queensland
Other
Load Incorporating Cardiac Assessment by Echocardiography In Patients With SEpsis: a Prospective Observational Study (LIAISE Study)
Acronym: LIAISE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07739004
Body Temperature Changes, Disease Attributes
Kayseri, Talas, Turkey (Türkiye)
View Trial DetailsNCT07739251
Infections, Inflammation
View Trial DetailsNCT07670624
Biomarker Discovery, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Wroclaw, Poland
View Trial DetailsNCT07735741
Infections, Inflammation
Falls Church, Virginia, United States
View Trial Details